Composition with effects of dispelling effects of alcohol and protecting liver as well as preparation method and application of composition

Abstract

The invention relates to the technical field of medicines, in particular to a composition with effects of dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 55 to 75 parts of puerarin, 20 to 40 parts of dihydromyricetin, 10 to 20 parts of myricetin, 6 to 12 parts of puerarin-4-beta-glucoside, 15 to 25 parts of 3 '-hydroxy puerarin, 20 to 30 parts of 3'-methoxy puerarin, 4 to 10 parts of vitexin, 4 to 10 parts of kaempferol and 2 to 6 parts of quercetin. The composition has the effects of resisting oxidation, dispelling the effects of alcohol and protecting the liver, and can obviously improve the drunkenness state, shorten the drunkenness time and promote the metabolism of alcohol in the body.

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and particularly relates to a composition with alcohol sobering and liver protecting effects, and a preparation method and application thereof. Background Art

[0002] The liver is an organ in the human body that detoxifies and metabolizes, and can break down alcohol. Most non-nutritional substances are broken down by the liver, and toxic substances are metabolized into non-toxic or low-toxic substances and excreted from the body. There are many reasons for liver damage, such as excessive alcohol, drugs or other toxic substances, and the degree of damage is related to time, dosage, toxicity and other conditions. Alcoholic liver damage is caused by long-term and heavy drinking, involving a series of liver injuries, from fatty liver to alcoholic, including early-stage fatty degeneration, alcoholic hepatitis, cirrhosis, and even advanced liver cancer.

[0003] The pathogenesis of alcoholic liver injury has been studied by a large number of scholars at home and abroad. After absorbing a large amount of alcohol, the dynamic balance of oxidants and antioxidants in the liver during the alcohol metabolism process is broken, resulting in the generation of "oxidative stress" pathological reactions; various normal metabolisms of the liver, such as lipid metabolism, protein metabolism and sugar metabolism, are disordered, leading to aggravated liver damage; after drinking alcohol, based on the "intestinal flora-intestine-liver axis" pathway, endotoxin enters the blood and activates liver macrophages, releasing a large number of cytokines and inflammatory factors, triggering liver inflammation; multiple cell signal transduction pathways are activated, autophagosomes and lysosomes are formed in large quantities, prompting apoptosis and autophagy of liver cells.

[0004] At present, anti-inflammatory and liver-protecting drugs, corticosteroids, and anti-liver fibrosis drugs are the main drugs for drug treatment on the market, and their therapeutic effects are limited. Even long-term use can easily cause new liver damage. Therefore, it is urgent to find safe, effective, and non-toxic alternative drugs. At present, a large number of studies have shown that Chinese medicine has great medicinal value in sobering up and protecting the liver. For example, Chinese invention patent application CN101785515A discloses a production method of wood honey sobering up tea, which solves the problem that the traditional drinking water, tea, and vinegar methods are slow to sober up, and the natural sobering drugs of kudzu root and kudzu flower have weak spleen and stomach functions and are not pure enough in medicinal properties. It is suitable for drinking and drunk people to soak; Chinese invention patent application CN106692342A discloses a sobering up Chinese medicine composition and application, which is composed of an ethanol extract of Hovenia dulcis, an ethanol extract of kudzu flower, and an ethanol extract of kudzu root. However, the above patent application has problems such as inconvenience in taking, large dosage, and the effect needs to be further improved. Summary of the invention

[0005] In view of the prior art, the present invention provides a composition with alcohol-relieving and liver-protecting effects, and a preparation method and application thereof. The composition with alcohol-relieving and liver-protecting effects can effectively slow down and protect the liver damage caused by alcohol, and has the advantages of easy administration, small dosage, good effect, etc.

[0006] To achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows: The first aspect of the present invention relates to a composition with alcohol sobering and liver protecting effects, which comprises, by weight: 55-75 parts of puerarin, 20-40 parts of dihydromyricetin, 10-20 parts of myricetin, 6-12 parts of puerarin-4-β-glucoside, 15-25 parts of 3′-hydroxypuerarin, 20-30 parts of 3′-methoxypuerarin, 4-10 parts of vitexin, 4-10 parts of kaempferol, and 2-6 parts of quercetin.

[0007] Preferably, the composition comprises, by weight: 60-75 parts of puerarin, 25-40 parts of dihydromyricetin, 12-18 parts of myricetin, 8-12 parts of puerarin-4-β-glucoside, 15-25 parts of 3′-hydroxypuerarin, 20-28 parts of 3′-methoxypuerarin, 6-10 parts of vitexin, 6-10 parts of kaempferol, and 3-6 parts of quercetin.

[0008] Preferably, the composition comprises, by weight: 60-70 parts of puerarin, 30-40 parts of dihydromyricetin, 12-18 parts of myricetin, 8-12 parts of puerarin-4-β-glucoside, 15-20 parts of 3′-hydroxypuerarin, 20-25 parts of 3′-methoxypuerarin, 6-8 parts of vitexin, 8-10 parts of kaempferol, and 4-6 parts of quercetin.

[0009] Preferably, the composition comprises, by weight: 65 parts of puerarin, 30 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3′-hydroxypuerarin, 25 parts of 3′-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0010] Preferably, the mass ratio of puerarin to dihydromyricetin is 1.5-3.5.

[0011] Preferably, the mass ratio of 3′-hydroxypuerarin to 3′-methoxypuerarin is 0.5-1.

[0012] The second aspect of the present invention relates to a method for preparing the above-mentioned composition having the effects of sobering up and protecting the liver, the preparation method comprising the following steps: mixing a formula amount of puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, 3′-methoxypuerarin, vitexin, kaempferol and quercetin to obtain the composition.

[0013] The third aspect of the present invention relates to the use of the above-mentioned composition with alcohol sobering and liver protecting effects in the preparation of products for anti-oxidation, alcohol sobering, and liver protection.

[0014] Preferably, the product is a medicine or a food.

[0015] Preferably, the dosage form of the product is solution, syrup, tablet, pill, cream, plaster, decoction, granule or capsule.

[0016] The beneficial effects of the present invention are as follows: (1) the composition can prolong the time for mice to fall asleep after drinking alcohol, and can also shorten the sleep time of mice after being drunk, that is, the righting reflex time of mice is shortened; (2) the composition promotes the metabolism of alcohol by the liver, and improves the effect of alcohol on the activity of MDA, SOD, and GSH-Px, and reduces their activity levels in serum; (3) the composition provided by the present invention has significantly improved effects when it is composed of specific components and in specific dosage ratios. The composition can be effectively used for anti-oxidation, sobering up from alcohol, and preventing or treating alcoholic liver damage. DETAILED DESCRIPTION

[0017] To illustrate the purpose, technical scheme and advantages of the present invention, the present invention is further described in detail below in conjunction with specific embodiments. In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further described below in conjunction with specific embodiments, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without making creative work belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, and the equipment materials used in each embodiment are the same. The present invention does not limit the source of the raw materials used. Unless otherwise specified, the raw materials used in the present invention are all common commercial products in the field of the present technology, and the purity is more than 98%. The raw material information in the formula of the present invention is shown in Table 1.

[0018] Table 1: Raw material information table in the formula of the present invention

[0019] Embodiment 1: The formula is as follows by weight: 70 parts of puerarin, 20 parts of dihydromyricetin, 10 parts of myricetin, 6 parts of puerarin-4-β-glucoside, 15 parts of 3′-hydroxypuerarin, 20 parts of 3′-methoxypuerarin, 4 parts of vitexin, 4 parts of kaempferol, and 2 parts of quercetin.

[0020] Preparation method: puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, 3′-methoxypuerarin, vitexin, kaempferol and quercetin in formulated amounts are mixed to obtain the composition.

[0021] Embodiment 2: The formula is as follows by weight: 55 parts of puerarin, 25 parts of dihydromyricetin, 10 parts of myricetin, 10 parts of puerarin-4-β-glucoside, 20 parts of 3′-hydroxypuerarin, 25 parts of 3′-methoxypuerarin, 6 parts of vitexin, 6 parts of kaempferol, and 4 parts of quercetin.

[0022] Preparation method: puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, 3′-methoxypuerarin, vitexin, kaempferol and quercetin in formulated amounts are mixed to obtain the composition.

[0023] Embodiment 3: The formula is as follows by weight: 60 parts of puerarin, 35 parts of dihydromyricetin, 15 parts of myricetin, 8 parts of puerarin-4-β-glucoside, 15 parts of 3′-hydroxypuerarin, 30 parts of 3′-methoxypuerarin, 8 parts of vitexin, 10 parts of kaempferol, and 6 parts of quercetin.

[0024] Preparation method: puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, 3′-methoxypuerarin, vitexin, kaempferol and quercetin in formulated amounts are mixed to obtain the composition.

[0025] Embodiment 4: The formula is as follows by weight: 65 parts of puerarin, 30 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3′-hydroxypuerarin, 25 parts of 3′-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0026] Preparation method: puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, 3′-methoxypuerarin, vitexin, kaempferol and quercetin in formulated amounts are mixed to obtain the composition.

[0027] The compositions of the formulations of Examples 1-4 in parts by weight are shown in Table 2.

[0028] Table 2: Formulations of Examples 1-4

[0029] Comparative Example 1: The formula is as follows by weight: 50 parts of puerarin, 45 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3′-hydroxypuerarin, 25 parts of 3′-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0030] The difference from Example 4 is that the amounts of puerarin and dihydromyricetin and the mass ratio of the two are different. In Example 4, puerarin is 65 parts, dihydromyricetin is 30 parts, and the mass ratio of the two is 2.17, while in Comparative Example 1, puerarin is 50 parts, dihydromyricetin is 45 parts, and the mass ratio of the two is 1.11.

[0031] The preparation method is the same as Example 4.

[0032] Comparative Example 2: The formula is as follows by weight: 95 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3′-hydroxypuerarin, 25 parts of 3′-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0033] The only difference from Example 4 is that puerarin is replaced by an equal amount of dihydromyricetin, and the rest is the same as Example 4.

[0034] Preparation method: dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, 3′-methoxypuerarin, vitexin, kaempferol and quercetin in prescribed amounts are mixed to obtain the composition.

[0035] Comparative Example 3: The formula is as follows by weight: 95 parts of puerarin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3′-hydroxypuerarin, 25 parts of 3′-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0036] The only difference from Example 4 is that dihydromyricetin is replaced by an equal amount of puerarin, and the rest is the same as Example 4.

[0037] Preparation method: puerarin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, 3′-methoxypuerarin, vitexin, kaempferol and quercetin in a prescribed amount are mixed to obtain the composition.

[0038] Comparative Example 4: The formula is as follows by weight: 65 parts of puerarin, 30 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 30 parts of 3′-hydroxypuerarin, 15 parts of 3′-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0039] The difference from Example 4 is that the amounts of 3′-hydroxypuerarin and 3′-methoxypuerarin and the mass ratio of the two are different. In Example 4, 3′-hydroxypuerarin is 20 parts, 3′-methoxypuerarin is 25 parts, and the mass ratio of the two is 0.8, while in Comparative Example 4, 3′-hydroxypuerarin is 30 parts, 3′-methoxypuerarin is 15 parts, and the mass ratio of the two is 2.

[0040] The preparation method is the same as Example 4.

[0041] Comparative Example 5: The formula is as follows by weight: 65 parts of puerarin, 30 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 45 parts of 3′-hydroxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0042] The difference from Example 4 is that 3′-methoxypuerarin is replaced by an equal amount of 3′-hydroxypuerarin, and the rest is the same as Example 4.

[0043] Preparation method: puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, vitexin, kaempferol and quercetin in a prescribed amount are mixed to obtain the composition.

[0044] Comparative Example 6: The formula is as follows by weight: 65 parts of puerarin, 30 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 45 parts of 3′-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol, and 4 parts of quercetin.

[0045] The difference from Example 4 is that 3′-hydroxypuerarin is replaced by an equal amount of 3′-methoxypuerarin, and the rest is the same as Example 4.

[0046] Preparation method: puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-methoxypuerarin, vitexin, kaempferol and quercetin in a prescribed amount are mixed to obtain the composition.

[0047] Experimental instruments: Infinite M200 PRO microplate reader, centrifuge, balance, cell disruptor, constant temperature water bath, scalpel, CO2 incubator.

[0048] Experimental materials: SPF Kunming mice, CCK-8 assay kit, RPMI1640 culture medium, and HepG2-human liver cancer cells were purchased from Wuhan Pronocell Life Science Co., Ltd. MDA kit, SOD kit, and GSH-Px kit were all purchased from Nanjing Jiancheng Biological Co., Ltd.

[0049] Experimental Example 1: In vitro antioxidant test: DPPH, ABTS+ antioxidant capacity determination, using DPPH, ABTS working solution reagents for antioxidant determination, each group of drug lyophilized powder gradient dilution to 0.025 mg / mL, 0.050 mg / mL, 0.100 mg / mL, 0.200 mg / mL, 0.400 mg / mL, 0.800 mg / mL, 1.000 mg / mL. Calculate its antioxidant capacity to get IC 50 value.

[0050] DPPH, ABTS+ antioxidant capacity IC of each group 50 The results of the (mg / mL) value determination are shown in Table 3.

[0051] Table 3: Antioxidant activity IC of each group 50 Value result (unit: mg / mL)

[0052] The results show that in the concentration range of 0.025-1.000 mg / mL, all have good antioxidant activity, among which Examples 1-4 have an IC of 1.000-1.000 mg / mL, compared with Comparative Examples 1-6. 50 Smaller, better antioxidant activity.

[0053] Experimental Example 2: Cell viability experiment: CCK8 was used to determine the cell viability of different groups of HepG2 cells after drug administration and the relevant cell viability IC was calculated 50 value.

[0054] Different concentrations of ethanol were used for modeling, including 1%, 2%, 3%, 4%, 5%, and 6% ethanol, to screen the appropriate modeling dose.

[0055] HepG2 cells were taken at 2×10 5 / mL was inoculated in a 12-well plate, 2 mL per well, and cultured for 24 h. After adding ethanol (final concentration of 4%) for modeling for 16 hours, different groups of drugs were added for intervention treatment, and the cells were collected for the determination of MDA, SOD, and GSH-Px biochemical indicators.

[0056] For cell viability experiments, the concentration range was controlled at 0-3.2 mg / mL, and the CCK8 reagent was used to calculate the cell viability IC 50 The results are shown in Table 4.

[0057] Table 4: IC of cell viability in each group 50 Value (unit: mg / mL)

[0058] According to the above results, compared with Comparative Examples 1-6, Examples 1-4 have higher concentrations, and stronger cell viability means lower toxicity.

[0059] The establishment of the ethanol-induced acute alcoholic liver injury model of HepG2 cells, the CCK8 reagent was used to calculate the cell viability (%), and the ethanol concentration is shown in Table 5. When the alcohol concentration was 0-6%, the cell survival rate decreased in a dose-dependent manner. As the alcohol concentration further increased to 5%, the cell viability dropped to 36.91%. At this time, alcohol showed a strong killing effect on cells, and the intracellular oxidative damage was severe, leading to a large number of cell apoptosis. After comprehensive consideration, 4% was selected as the appropriate alcohol concentration to establish the alcohol-induced HepG2 cell oxidative damage model for subsequent experiments.

[0060] Table 5: Cell viability test ethanol concentration screening experiment

[0061] The anti-oxidative damage ability of HepG2 cells was measured by SOD, MDA and GSH-Px kits as shown in Table 6.

[0062] Table 6: Effects on the anti-oxidative damage ability of HepG2 cells

[0063] Note: Compared with the blank group, # P<0.05; compared with the model group; * P<0.05, ** P<0.01; compared with Example 4, □□P<0.01 among the drug-treated groups.

[0064] Compared with the blank group, the activities of SOD and GSH-Px in the model group were significantly reduced ( P <0.05), MDA content increased significantly ( P <0.05) indicates that the modeling was successful. Compared with the model group, the drugs in Examples 1-4 and Comparative Examples 1-6 had a positive regulatory effect on the activity of SOD, GSH-Px and MDA content, and the difference was statistically significant ( P <0.05) or significant difference ( P <0.01). Compared with Example 4, the effects of Examples 1-3 are equivalent to those of Example 4, and are significantly better than the effects of the drugs in Comparative Examples 1-6. The composition provided by the present invention has a better positive regulating effect on SOD, GSH-Px activity and MDA content.

[0065] Experimental Example 3: Animal experiment: The compositions with alcohol sobering and liver protecting effects prepared in Examples 1-4 and the compositions prepared in Comparative Examples 1-6 were administered to KM mice, respectively, and a blank group mouse experiment was set up. Before the experiment, the drugs in Examples 1-4 and Comparative Examples 1-6 were dissolved in physiological saline.

[0066] The groups were divided into blank group, model group, and drug administration group (Example 1-Example 4, Comparative Example 1-Comparative Example 6), wherein the blank group and the model group were gavaged with 5 mL / kg of normal saline, and each Example group and the Comparative Example group were given the corresponding composition for continuous gavage for 21 days, once a day, with a dosage of 11 g / kg•bw, gavage at 5 mL / kg body weight, and administration was performed in the morning of the 22nd to 28th day, and 50% alcohol was gavaged in the afternoon, and the alcohol gavage dosage was gradually increased from 4 mg / g to 6 mg / g, and the dosage was adjusted by weighing every three days. After the last administration, the mice in each group were strictly fasted but not water-free for 16 hours, the eyeballs were removed for blood collection, the liver was dissected and removed, and the data were recorded, and the relevant indicators were tested.

[0067] Intoxication sleep experiment: The activities of mice after drinking on the 28th day were recorded. Unsteady crawling, slow movements, and laziness with eyes closed were taken as indicators of sleep or intoxication. Free movement, flexible limbs, and normal mental state of the mice were taken as indicators of awakening or sobering up. The time of falling asleep and waking up were recorded, and the sleep tolerance time (i.e., the time from drinking to falling asleep) and duration (i.e., the time from falling asleep to waking up) were calculated, in min.

[0068] Detection of antioxidant indexes in mouse liver: Take an appropriate amount of liver and homogenize it, 10% liver tissue homogenate, and detect the contents of MDA, SOD, GSH-Px, etc. in mouse liver according to the kit operation.

[0069] The results of the drunken sleep experiment are shown in Table 7.

[0070] Table 7: Sleep tolerance time after alcohol gavage on day 28 (min, n=10, mean ± standard deviation)

[0071] Note: Compared with the blank group, ## P<0.01; compared with the model group; * P<0.05, ** P<0.01; compared with Example 4, ○P<0.05, ○○P<0.01 among the drug-treated groups.

[0072] In the observation after the mice were given alcohol on the 28th day, the effect of the composition with alcohol sobering and liver protecting effects prepared in Examples 1-4 on the sleep tolerance time and sleep duration of mice was more significant than that in Comparative Examples 1-3.

[0073] The test results of mouse liver antioxidant indexes are shown in Table 8.

[0074] Table 8: Effects on the contents of related components in mouse liver (mean ± standard deviation, n = 10)

[0075] Note: Compared with the blank group, # P<0.05; compared with the model group; * P<0.05, ** P<0.01; compared with Example 4, among the drug-administered groups, ○P<0.05, ○○P<0.01.

[0076] The content of MDA is an important parameter reflecting the body's potential antioxidant capacity, which can reflect the body's lipid peroxidation rate and intensity, and can also indirectly reflect the degree of tissue peroxidation damage. The drugs of Examples 1-4 and Comparative Examples 1-6 can all reduce the MDA content of model mice, but the degree of reduction of the MDA content of Example 1-4 is significantly better than that of Comparative Examples 1-6. SOD and GSH-Px are important antioxidant enzymes in organisms. Through cooperative action, they convert reactive oxygen species into harmless substances and protect cells from oxidative damage. At the same time, they can also be used as indicators of the degree of oxidative stress in organisms to reflect the health status of organisms. It can be seen from the table that the drugs of Examples 1-4 and Comparative Examples 1-6 can all increase the SOD and GSH-Px contents of model mice, but the effect of Example 1-4 is significantly better than that of the Comparative Example 1-6 group.

[0077] It can be seen from the above data that the composition of the present invention can significantly improve the effect of alcohol on the drunkenness and soberness time of mice, and can also significantly improve related biochemical indicators, such as MDA, SOD, and GSH-Px oxidation indicators in the liver, which proves that the composition has the activity of resisting alcoholic liver injury and its possibility as an anti-alcoholic liver injury. The effect of the composition in the embodiment of the present invention is significantly better than that of the comparative examples. The composition provided by the present invention can more effectively prevent or reduce alcohol damage to the liver.

[0078] It can be seen from this that the composition of the present invention can prevent or alleviate alcohol damage to the liver to a certain extent.

[0079] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A composition having the effects of sobering up and protecting the liver, characterized in that: The composition comprises, by weight, 55-75 parts of puerarin, 20-40 parts of dihydromyricetin, 10-20 parts of myricetin, 6-12 parts of puerarin-4-β-glucoside, 15-25 parts of 3′-hydroxypuerarin, 20-30 parts of 3′-methoxypuerarin, 4-10 parts of vitexin, 4-10 parts of kaempferol and 2-6 parts of quercetin.

2. The composition having alcohol sobering and liver protecting effects according to claim 1, characterized in that: The composition comprises, by weight, 60-75 parts of puerarin, 25-40 parts of dihydromyricetin, 12-18 parts of myricetin, 8-12 parts of puerarin-4-β-glucoside, 15-25 parts of 3′-hydroxypuerarin, 20-28 parts of 3′-methoxypuerarin, 6-10 parts of vitexin, 6-10 parts of kaempferol and 3-6 parts of quercetin.

3. The composition having alcohol sobering and liver protecting effects according to claim 1, characterized in that: The composition comprises, by weight, 60-70 parts of puerarin, 30-40 parts of dihydromyricetin, 12-18 parts of myricetin, 8-12 parts of puerarin-4-β-glucoside, 15-20 parts of 3′-hydroxypuerarin, 20-25 parts of 3′-methoxypuerarin, 6-8 parts of vitexin, 8-10 parts of kaempferol and 4-6 parts of quercetin.

4. The composition having the effects of sobering up and protecting the liver according to claim 1, characterized in that: The composition comprises, by weight, 65 parts of puerarin, 30 parts of dihydromyricetin, 18 parts of myricetin, 12 parts of puerarin-4-β-glucoside, 20 parts of 3′-hydroxypuerarin, 25 parts of 3′-methoxypuerarin, 6 parts of vitexin, 8 parts of kaempferol and 4 parts of quercetin.

5. The composition having alcohol sobering and liver protecting effects according to any one of claims 1 to 4, characterized in that: The mass ratio of puerarin to dihydromyricetin is 1.5-3.

5.

6. The composition having the effects of sobering up and protecting the liver according to any one of claims 1 to 4, characterized in that: The mass ratio of the 3'-hydroxypuerarin to the 3'-methoxypuerarin is 0.5-1.

7. The method for preparing the composition having alcohol sobering and liver protecting effects according to any one of claims 1 to 6, characterized in that: The method comprises the following steps: mixing the formulated amounts of puerarin, dihydromyricetin, myricetin, puerarin-4-β-glucoside, 3′-hydroxypuerarin, 3′-methoxypuerarin, vitexin, kaempferol and quercetin to obtain the obtained product.

8. Use of the composition with alcohol sobering and liver protecting effects according to any one of claims 1 to 6 or the composition with alcohol sobering and liver protecting effects obtained by the preparation method according to claim 7 in the preparation of products for anti-oxidation, alcohol sobering, and liver protection.

9. The use according to claim 8, characterized in that: The product is a medicine or a food.

10. The use according to claim 8, characterized in that: The dosage form of the product is solution, syrup, tablet, pill, cream, plaster, decoction, granule or capsule.

Images